CY1117355T1 - Μονοκλωνικα αντισωματα αντi-φερροπορτiνης 1 και χρησεις αυτων - Google Patents
Μονοκλωνικα αντισωματα αντi-φερροπορτiνης 1 και χρησεις αυτωνInfo
- Publication number
- CY1117355T1 CY1117355T1 CY20161100296T CY161100296T CY1117355T1 CY 1117355 T1 CY1117355 T1 CY 1117355T1 CY 20161100296 T CY20161100296 T CY 20161100296T CY 161100296 T CY161100296 T CY 161100296T CY 1117355 T1 CY1117355 T1 CY 1117355T1
- Authority
- CY
- Cyprus
- Prior art keywords
- antibodies
- monoclonic
- ferroportin
- maintaining
- reticulocytes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12007608P | 2008-12-05 | 2008-12-05 | |
| US23981809P | 2009-09-04 | 2009-09-04 | |
| EP09760073.8A EP2373335B1 (en) | 2008-12-05 | 2009-12-01 | Anti-ferroportin 1 monoclonal antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1117355T1 true CY1117355T1 (el) | 2017-04-26 |
Family
ID=41683589
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20161100296T CY1117355T1 (el) | 2008-12-05 | 2016-04-12 | Μονοκλωνικα αντισωματα αντi-φερροπορτiνης 1 και χρησεις αυτων |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP2373335B1 (enExample) |
| JP (1) | JP5713917B2 (enExample) |
| KR (1) | KR101353117B1 (enExample) |
| CN (1) | CN102238962B (enExample) |
| AR (1) | AR074398A1 (enExample) |
| AU (1) | AU2009322587B2 (enExample) |
| BR (1) | BRPI0922288A2 (enExample) |
| CA (1) | CA2745618C (enExample) |
| CY (1) | CY1117355T1 (enExample) |
| DK (1) | DK2373335T3 (enExample) |
| EA (1) | EA020472B1 (enExample) |
| ES (1) | ES2566343T3 (enExample) |
| HR (1) | HRP20160302T1 (enExample) |
| HU (1) | HUE028585T2 (enExample) |
| IL (1) | IL212731A0 (enExample) |
| MX (1) | MX2011005939A (enExample) |
| NZ (1) | NZ592545A (enExample) |
| PA (1) | PA8849601A1 (enExample) |
| PL (1) | PL2373335T3 (enExample) |
| SG (1) | SG171960A1 (enExample) |
| SI (1) | SI2373335T1 (enExample) |
| TW (1) | TW201023891A (enExample) |
| UA (1) | UA104741C2 (enExample) |
| WO (1) | WO2010065496A1 (enExample) |
| ZA (1) | ZA201103941B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014027905A2 (pt) * | 2012-05-14 | 2017-06-27 | Genentech Inc | anticorpo, célula, ácido nucleico, métodos de identificação de um primeiro anticorpo, de inibição do crescimento de uma célula, de tratamento terapêutico, de determinação da presença de uma proteína, de diagnóstico da presença de um tumor e de distribuição de agente citotóxico. |
| WO2019213016A1 (en) | 2018-04-30 | 2019-11-07 | The Children's Hospital Of Philadelphia | Methods of improving anemias by combining agents |
| CA3156007A1 (en) | 2019-09-27 | 2021-04-01 | Disc Medicine, Inc. | METHODS OF TREATING MYELOFIBROSE AND ASSOCIATED CONDITIONS |
| CN110806486B (zh) * | 2019-11-23 | 2023-03-21 | 中南大学湘雅三医院 | Mafg/as1/pcbp2/fpn1调控轴作为靶位点检测试剂的应用 |
| AU2021273014A1 (en) | 2020-05-13 | 2022-11-17 | AbbVie Deutschland GmbH & Co. KG | Anti-hemojuvelin (HJV) antibodies for treating anemia of chronic disease |
| ES3075793T3 (en) | 2020-05-13 | 2026-08-07 | Disc Medicine Inc | Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis |
| CN113980987A (zh) * | 2021-12-06 | 2022-01-28 | 上海市农业科学院 | 一种提高植物抗镍性能的PgIREG1S和AlATP-PRTS双基因组及其应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7166448B1 (en) * | 1999-05-10 | 2007-01-23 | Children's Medical Center Corproation | Ferroportin1 nucleic acids and proteins |
| IT1319221B1 (it) * | 2000-10-17 | 2003-09-26 | Antonello Pietrangelo | Mutazioni nel gene della ferroportina 1 associata ad emocromatosiereditaria. |
| EP2803675A3 (en) * | 2008-01-25 | 2014-12-24 | Amgen, Inc | Ferroportin antibodies and methods of use |
-
2009
- 2009-11-23 PA PA20098849601A patent/PA8849601A1/es unknown
- 2009-11-24 AR ARP090104529A patent/AR074398A1/es unknown
- 2009-11-25 TW TW098140185A patent/TW201023891A/zh unknown
- 2009-12-01 DK DK09760073.8T patent/DK2373335T3/en active
- 2009-12-01 EA EA201170764A patent/EA020472B1/ru not_active IP Right Cessation
- 2009-12-01 MX MX2011005939A patent/MX2011005939A/es active IP Right Grant
- 2009-12-01 ES ES09760073.8T patent/ES2566343T3/es active Active
- 2009-12-01 UA UAA201107028A patent/UA104741C2/uk unknown
- 2009-12-01 KR KR1020117014053A patent/KR101353117B1/ko not_active Expired - Fee Related
- 2009-12-01 JP JP2011539625A patent/JP5713917B2/ja not_active Expired - Fee Related
- 2009-12-01 BR BRPI0922288A patent/BRPI0922288A2/pt not_active IP Right Cessation
- 2009-12-01 SG SG2011040797A patent/SG171960A1/en unknown
- 2009-12-01 NZ NZ592545A patent/NZ592545A/xx not_active IP Right Cessation
- 2009-12-01 AU AU2009322587A patent/AU2009322587B2/en not_active Ceased
- 2009-12-01 EP EP09760073.8A patent/EP2373335B1/en active Active
- 2009-12-01 SI SI200931382T patent/SI2373335T1/sl unknown
- 2009-12-01 PL PL09760073T patent/PL2373335T3/pl unknown
- 2009-12-01 CN CN200980148354.8A patent/CN102238962B/zh not_active Expired - Fee Related
- 2009-12-01 WO PCT/US2009/066187 patent/WO2010065496A1/en not_active Ceased
- 2009-12-01 HR HRP20160302TT patent/HRP20160302T1/hr unknown
- 2009-12-01 CA CA2745618A patent/CA2745618C/en not_active Expired - Fee Related
- 2009-12-01 HU HUE09760073A patent/HUE028585T2/en unknown
-
2011
- 2011-05-05 IL IL212731A patent/IL212731A0/en unknown
- 2011-05-27 ZA ZA2011/03941A patent/ZA201103941B/en unknown
-
2016
- 2016-04-12 CY CY20161100296T patent/CY1117355T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010065496A1 (en) | 2010-06-10 |
| AR074398A1 (es) | 2011-01-12 |
| JP2012510814A (ja) | 2012-05-17 |
| CA2745618C (en) | 2014-06-10 |
| JP5713917B2 (ja) | 2015-05-07 |
| CA2745618A1 (en) | 2010-06-10 |
| AU2009322587A1 (en) | 2011-07-28 |
| EA201170764A1 (ru) | 2011-12-30 |
| HUE028585T2 (en) | 2016-12-28 |
| HK1158977A1 (zh) | 2012-07-27 |
| KR20110084996A (ko) | 2011-07-26 |
| UA104741C2 (uk) | 2014-03-11 |
| AU2009322587B2 (en) | 2013-09-26 |
| CN102238962A (zh) | 2011-11-09 |
| SG171960A1 (en) | 2011-07-28 |
| KR101353117B1 (ko) | 2014-02-17 |
| EP2373335A1 (en) | 2011-10-12 |
| MX2011005939A (es) | 2011-06-27 |
| IL212731A0 (en) | 2011-07-31 |
| TW201023891A (en) | 2010-07-01 |
| PL2373335T3 (pl) | 2016-08-31 |
| SI2373335T1 (sl) | 2016-04-29 |
| HRP20160302T1 (hr) | 2016-04-22 |
| NZ592545A (en) | 2012-12-21 |
| EA020472B1 (ru) | 2014-11-28 |
| ES2566343T3 (es) | 2016-04-12 |
| BRPI0922288A2 (pt) | 2018-08-28 |
| DK2373335T3 (en) | 2016-05-02 |
| CN102238962B (zh) | 2014-02-12 |
| ZA201103941B (en) | 2012-11-28 |
| PA8849601A1 (es) | 2010-07-27 |
| EP2373335B1 (en) | 2016-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1122816T1 (el) | Στοχοθετημενοι συνδετικοι παραγοντες εναντι β7-η1 | |
| CY1122658T1 (el) | Αντισωματα συνδεσης ανθρωπινου cgrp υποδοχεα | |
| CY1122210T1 (el) | Ανθρωπινα αντισωματα anti-sod1 | |
| EP2210939A4 (en) | Anti-bst2 antibody | |
| CY1122458T1 (el) | Αντισωματα αντι-n3pglu αμυλοειδους βητα πεπτιδιου και χρησεις αυτων | |
| CY1118880T1 (el) | Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις | |
| CY1121294T1 (el) | Αντι-ilt7 αντισωμα | |
| CY1119994T1 (el) | Συνθεσεις και μεθοδοι για αυξηση της μυϊκης μαζας και της μυϊκης δυναμης ανταγωνιζοντας ειδικα ton gdf8 και/ή την ακτιβινη α | |
| CY1119591T1 (el) | Πρωτεϊνες ειδικης συνδεσης και χρησεις αυτων | |
| CR11282A (es) | Proteinas enlazadas al antigeno de celula de cepa mcdonough de felino humanas | |
| BR112012023010A2 (pt) | "anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37" | |
| CY1114658T1 (el) | Πρωτεϊνες δεσμευσης αντιγονου του αυξητικου παραγοντα τυπου επιδερμικου αυξητικου παραγοντα προσδεσης στην ηπαρινη | |
| TR201900975T4 (tr) | Yetişkin multipotansiyel mezenkimal prekürsör hücrelerin tanımlaması ve/veya zenginleştirmesi için markör olarak ısı şok proteini 90-beta'nın kullanımı. | |
| UA113609C2 (xx) | Антигензв'язуючий білок, який зв'язує людський il-23 | |
| CY1118928T1 (el) | Αντι-οχ40 αντισωματα και μεθοδοι χρησης τους | |
| ATE497508T1 (de) | Gegen das säugetier-eag1-ionenkanalprotein gerichtete antikörper | |
| CY1116886T1 (el) | C-met αντισωματα | |
| EA200970108A1 (ru) | Композиции и способы для ингибирования роста smad4-дефицитных форм рака | |
| DE602005027820D1 (de) | Mehrfachpromotor-expressionskassetten zurgleichzeitigen zuführung von rnai-agentien | |
| CY1121368T1 (el) | Αντισωματα anti-asic1 και χρησεις αυτων | |
| CY1117695T1 (el) | Υψηλης συγγενειας ανθρωπινα αντισωματα κατα της ανθρωπινης αγγειοποιητινης-2 | |
| ATE505544T1 (de) | Monoklonale antikörper und einzelkettenantikörper fragments gegen das zelloberflächen prostataspezifische membranantigen | |
| BR112015014751A2 (pt) | anticorpos anti-tau humanos | |
| BR112014028785A2 (pt) | proteínas de ligação a antígeno de st2 | |
| BR112014015152A2 (pt) | métodos e materiais para a avaliação da perda de heterozigosidade |